Cytopenias Did Not Affect Ruxolitinib Efficacy in REACH2 Post Hoc Analysis
February 17th 2023Ruxolitinib elicited higher responses at day 28 compared with best available therapy in most cytopenia-based subgroups and had durable responses at day 56, according to a post hoc analysis of the REACH2 trial.
Primary End Point of Improved DFS Not Met With Adjuvant Canakinumab in NSCLC
September 12th 2022Adjuvant treatment with canakinumab did not meet the disease-free survival primary end point in patients with completely resected non–small cell lung cancer versus placebo, nor did subgroup analyses show statistically significant differences in DFS, according to results from the phase 3 CANOPY-A trial presented at ESMO Congress 2022.
Neoadjuvant Nivolumab/Ipilimumab Shows Unprecedented Pathologic Responses in dMMR Colon Cancer
September 11th 2022At the 2022 ESMO Congress, results from the NICHE-2 trial showed neoadjuvant immunotherapy in patients with mismatch repair deficient colon cancer had notable responses to the therapy well above neoadjuvant chemotherapy.
Interim Data Targeting CD117 Show Promising MRD Results and Safety in MDS/AML
April 27th 2022JSP191 combined with fludarabine, and low-dose total body radiation demonstrated facilitation of full donor myeloid chimerism, clearing of minimal residual disease, and a well-tolerated safety profile in older patients with myelodysplastic syndrome/acute myeloid leukemia receiving non-myeloablative allogenic hematopoietic cell transplantation.
Nivolumab/Cabozantinib Combo Shows Lasting OS Benefit for RCC in Final Analysis
February 19th 2022In a final overall survival analysis of CheckMate 9ER, investigators saw a continued survival benefit with first-line nivolumab plus cabozantinib compared with sunitinib in the intention-to-treat patients with untreated clear cell metastatic or advanced renal cell carcinoma.
Venetoclax With Acalabrutinib or Obinutuzumab Evaluated in Treatment-Naive CLL/SLL
December 12th 2021In a randomized phase 3 trial, acalabrutinib plus venetoclax versus obinutuzumab plus venetoclax will be investigated for efficacy and safety with a noninferiority design in patients with previously untreated chronic lymphocytic leukemia/small lymphocytic leukemia.
SITC Releases Immunotherapy Clinical Practice Guideline for Breast Cancer
August 23rd 2021In the wake of immunotherapy combinations becoming available in breast cancer, including triple-negative breast cancer, the Society for Immunotherapy of Cancer has published clinical practice guidelines for physicians treating in this setting.
Experts Discuss the Spearhead 1 Trial and Other ASCO Data for Sarcoma Awareness Month
July 26th 2021During the 2021 American Society of Clinical Oncology Annual Meeting, multiple trials for targeted treatments were presented for soft tissue sarcoma. Dean Frohlich, PhD, and Brian A. Van Tine, MD, PhD, discuss the the results of some of these presentations, including the Spearhead 1 trial.